Product Name:1-(((cyclohexyloxy)carbonyl)oxy)ethyl 3-((2'-(2-ethyl-2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-4-carboxylate
IUPAC Name:1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 3-{[2'-(2-ethyl-2H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-2-oxo-2,3-dihydro-1H-1,3-benzodiazole-4-carboxylate
| Packing Unit | Available Stock | Price($) | Quantity |
|---|
| Product Overview |
2-Desethoxy-2-oxo-2H-2-ethyl candesartan cilexetil (DECC) is a novel synthetic compound that has recently been studied for its potential pharmacological applications. DECC is an angiotensin II receptor blocker (ARB) that has been developed to provide therapeutic benefits in the treatment of hypertension and other cardiovascular diseases. The compound is a prodrug, which means that it is inactive until it is metabolized in the body and converted into its active form. DECC has been found to possess a wide range of pharmacological activities, including anti-inflammatory, anti-oxidant, and anti-platelet activities. |
| Synthesis Method |
2-Desethoxy-2-oxo-2H-2-ethyl candesartan cilexetil is synthesized through a multi-step process involving the synthesis of the parent compound, candesartan cilexetil (CC), followed by the introduction of the 2-desethoxy-2-oxo-2H-2-ethyl moiety. The synthesis of CC involves the reaction of 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid with the amine 4-amino-2-butyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid. The 2-desethoxy-2-oxo-2H-2-ethyl moiety is then introduced to the CC molecule by the reaction of the CC with 2-ethoxy-2-oxo-2H-2-ethyl acetate in the presence of a base. |
| Synthesis and Application |
2-Desethoxy-2-oxo-2H-2-ethyl candesartan cilexetil has been studied for its potential pharmacological applications, particularly in the treatment of hypertension and other cardiovascular diseases. Studies have shown that 2-Desethoxy-2-oxo-2H-2-ethyl candesartan cilexetil is a potent angiotensin II receptor blocker (ARB) with a high affinity for the AT1 receptor subtype. 2-Desethoxy-2-oxo-2H-2-ethyl candesartan cilexetil is also a highly lipophilic compound that is rapidly absorbed and distributed throughout the body. This makes it an ideal candidate for the treatment of hypertension and other cardiovascular diseases, as it can be quickly and effectively delivered to the target sites in the body. |
| Future Directions |
The potential future directions for 2-Desethoxy-2-oxo-2H-2-ethyl candesartan cilexetil include further research into its pharmacological applications, particularly in the treatment of hypertension and other cardiovascular diseases. Additionally, further research into the biochemical and physiological effects of 2-Desethoxy-2-oxo-2H-2-ethyl candesartan cilexetil could yield new therapeutic applications for the drug. Additionally, further research into the mechanism of action of 2-Desethoxy-2-oxo-2H-2-ethyl candesartan cilexetil could reveal new therapeutic. |
Search 
+86 21 5895 0110 
